Matthew Hebden Porteus is the Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University. In 2003, while working as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus showed for the first time that precise changes could be made to genes in human cells using special tools called chimeric nucleases.

He graduated with high honors from Harvard University and earned both his MD and PhD degrees at Stanford University. During his post-doctoral training, he worked with David Baltimore at MIT and Caltech. He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.

According to Google Scholar, his research has an h-index of 69.